Spyre Therapeutics Inc (SYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Operating Expenses | 21,909 | 22,146 | 18,622 | 17,657 | 15,305 |
| Operating Income | -21,909 | -22,146 | -18,622 | -17,657 | -15,305 |
| Other Income | 414 | 573 | 603 | 490 | 407 |
| Pre-tax Income | -21,495 | -21,573 | -18,019 | -17,167 | -14,898 |
| Net Income Continuous | -21,495 | -21,573 | -18,019 | -17,167 | -14,898 |
| Net Income | $-21,495 | $-21,573 | $-18,019 | $-17,167 | $-14,898 |
| EPS Basic Total Ops | -16.25 | -16.50 | -13.75 | -14.75 | -16.00 |
| EPS Basic Continuous Ops | -16.33 | -16.40 | -13.72 | -14.79 | -16.09 |
| EPS Diluted Total Ops | -16.25 | -16.50 | -13.75 | -14.75 | -16.00 |
| EPS Diluted Continuous Ops | -16.33 | -16.40 | -13.72 | -14.79 | -16.09 |
| EBITDA(a) | $-21,872 | $-22,247 | $-18,783 | $-17,832 | $-15,515 |